Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study

British Journal of Ophthalmology

Volumn 95, Issue 5, 2011, Pages 657-661

  Vadalà, Maria ^a   Pece, Alfredo ^b   Cipolla, Stefano ^a   Monteleone, Carla ^a   Fasolino, Giuseppe ^c   Casuccio, Alessandra ^a   Cillino, Salvatore ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Ospedale di Melegnano   (Italy)

^c Unità Operativa di Chirurgia Oculistica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; AGE; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MALE; MULTICENTER STUDY; MYOPIA; OPEN STUDY; OPTICAL RESOLUTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTION ERROR; RETINA DETACHMENT; RETINA TEAR; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; OFF-LABEL USE; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 79955018504     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.174243     Document Type: Article

References (24)

1. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization. Ophthalmology 2003;110:1297-305.
2. Soubrane G. Choroiodal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Survey Ophthalmol 2008; 53:121-38. (Pubitemid 351381556)
3. Brancato R, Pece A, Avanza P, et al. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia. Retina 1990;10:239-43.
4. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-Vip report No 1. Ophthalmology 2001; 108:841-52.
5. Pece A, Isola V, Vadalà M, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: a long-term study. Retina 2006;26:746-51. (Pubitemid 44386095)
6. Pece A, Vadalà M, Isola V, et al. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularizzation in pathologic myopia: a long-term follow-up Study. Am J Ophthalmol 2007;143:449-54.
7. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100.
8. Gharbiya M, Allievi F, Mazzeo L, et al. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009;147:84-93.
9. Silva RM, Ruiz-Moreno JM, Nascimento J, et al. Short-term efficacy of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008;28:1117-23.
10. Kostantidinis L, Mantel I, Pournaras JAC, et al. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:311-18.
11. Mones JM, Amselm L, Serrano A, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye 2009;23:1275-80.
12. Lai TY, Chan WM, Liu DT, et al. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009;29:750-6.
13. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:S3-19.
14. Secretan M, Kuhn D, Soubrane G, et al. Long-term visual outcome of choroidal neovascularization in pathologic myopia. Natural history and laser treatment. Eur J Ophthalmol 1997;7:307-16. (Pubitemid 28042043)
15. Krebs I, Binder S, Stolba U, et al. Choroidal neovascularization in pathologic myopia: three-year result after photodynamic therapy. Am J Ophthalmol 2005;140:416-25.
16. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
17. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009;20:158-65.
18. McKay GJ, Silvestri G, Orr N, et al. VEGF and age-related macular degeneration. Ophthalmology. 2009;116:1227.e1-3.
19. Chan WM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008;28:1308-13.
20. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009;54:372-400.
21. Ruiz- Moreno JM, Montero JA. Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularization in highly myopic eyes. Br J Ophthalmol 2003;87:856-9. (Pubitemid 36765249)
22. Grossniklaus HE, Gass JDM. Clinicopathologic correlation of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 1998;126:59-69. (Pubitemid 28341219)
23. Ergun E, Heinzl H, Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 2004;138:434-8. (Pubitemid 39208575)
24. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.